Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. ecmo-biomarker

ECMO-BIOMARKER SIGNED

Delivering ECMO-BIOMARKER – a ground-breaking ICT-enabled ECMO Biomarker system providing clinicians with bedside decision support for better care and reduced costs of severe ICU patients

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 ECMO-BIOMARKER project word cloud

Explore the words cloud of the ECMO-BIOMARKER project. It provides you a very rough idea of what is the project "ECMO-BIOMARKER" about.

royal    market    patients    doctors    group    costing    reduce    tools    2025    160m    skilled    patient    oxygenized    site    vienna    characterised    potentially    fr    biomarker    48m    companion    brompton    cut    16    ferrand    membrane    icu    hospitalier    23    action    quality    rudimentary    corporal    proposition    ventilation    annually    industry    diagnose    imperial    universitaire    algorithms    minutes    bedside    clermont    external    mermaid    centre    26bn    university    respiratory    ten    patents    diagnosis    uk    sales    clinically    dk    model    referrals    diagnostic    innovation    hire    oxygenation    treatment    conventional    injury    recommendations    college    extra    healthcare    hospitals    tool    function    predictive    accurate    ecmo    one    empowers    acute    aalborg    perform    employees    instead    clinical    slashing    first    uses    world    workflow    severe    documented    london    machine    physiological    intensive    lung    hospital    care    blood    medical    ict    20    launched    de    centres   

Project "ECMO-BIOMARKER" data sheet

The following table provides information about the project.

Coordinator		 MERMAID CARE AS 

Organization address
address: HEDELUND 1
city: NORRESUNDBY
postcode: 9400
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Denmark [DK]
 Total cost 3˙558˙966 €
 EC max contribution 2˙851˙191 € (80%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-EIC-FTI-2018-2020
 Funding Scheme IA
 Starting year 2019
 Duration (year-month-day) from 2019-04-01   to  2021-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    MERMAID CARE AS DK (NORRESUNDBY) coordinator 1˙651˙475.00
2    IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE UK (LONDON) participant 625˙312.00
3    CENTRE HOSPITALIER UNIVERSITAIRE DE CLERMONT-FERRAND FR (CLERMONT FERRAND) participant 215˙155.00
4    AALBORG UNIVERSITET DK (AALBORG) participant 195˙000.00
5    MEDIZINISCHE UNIVERSITAET WIEN AT (WIEN) participant 164˙248.00

Map

 Project objective

One out of ten ICU respiratory patients are characterised as being “severe”, with a lung function of less than 20% due to acute respiratory failure. This group are often referred to ECMO (Extra Corporal Membrane Oxygenation) treatment, in which the patient’s blood is oxygenized by an external machine, costing European healthcare centres €26Bn annually. The problem is, due to the rudimentary tools that ICU doctors use to diagnose these patients, 20% of all ECMO patients should not have been treated with ECMO and instead could have stayed in conventional intensive ventilation care. Industry partner Mermaid Care aims to solve this problem with ECMO-BIOMARKER – the world’s first biomarker-based companion diagnostic tool for severe lung injury patients. ECMO-BIOMARKER will potentially reduce ECMO referrals by 10-20%, slashing costs for the average European ECMO centre by an estimated €23-48M annually. Based on clinically predictive biomarker measurements, ECMO-BIOMARKER uses novel algorithms and physiological model to deliver accurate diagnosis recommendations for each patient, bedside and in less than 2 minutes. This ICT-approach changes workflow and empowers low-skilled ICU doctors to perform ECMO diagnosis. In the proposed action, ECMO-BIOMARKER value proposition (reduction in ECMO patients) will be clinically documented together with 4 world-leading partners in the field of ICU management and ECMO treatment: 3 clinical research partners – Imperial College London with the clinical site Royal Brompton Hospital (UK), Medical University of Vienna (AT) and Centre Hospitalier Universitaire de Clermont-Ferrand (FR) – and research partner Aalborg University (DK). After the project, ECMO-BIOMARKER is launched on the EU market, allowing European hospitals to cut ICU costs and improve patient quality of care. This project will allow Mermaid Care to reach sales of €160M in 2025 and hire 30 new employees. The innovation is based on 16 years of research and 10 patents.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ECMO-BIOMARKER" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ECMO-BIOMARKER" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.1.)

PATH-TOX (2018)

Artificial Intelligence to transform Drug and Chemical safety testing

Read More  

ENHANCEplayer (2018)

An Artificial Intelligence Enhancing Video Quality Locally to Limit Internet Traffic Tied to Video Streaming

Read More  

De-RISC (2019)

De-RISC: Dependable Real-time Infrastructure for Safety-critical Computer

Read More